News

HDA Media And Political Bulletin – 31 May 2016

Association of the British Pharmaceutical Industry warns against Brexit

27 May 2016, The Pharmaceutical Journal

 

The ABPI has called for the UK to remain in the European Union, arguing that EU membership enhances patients’ access to innovative clinical research. Mike Thompson, ABPI chief executive warned that the UK legacy of a “go-to place for clinical trial” would be threatened. In addition, the Association predicts that the EU Clinical Trials Regulation set to come into force in 2018 will remove a lot of the red tape associated with the EU.

 

###

 

Alistair Burt in a debate at the House of Commons announced that plans for community pharmacy will be announced in July 2016. The full story is available in The Pharmaceutical Journal and on the DDA website.

 

Pharmacy Biz (here and here) report on the ongoing campaign against planned pharmacy funding cuts, discussed at the Avicenna conference.

 

Parliamentary Coverage

 

There is no Parliamentary coverage today.

 

Full Coverage

Association of the British Pharmaceutical Industry warns against Brexit

27 May 2016, The Pharmaceutical Journal

 

The Association of the British Pharmaceutical Industry (ABPI), a trade association of companies in the UK producing prescription medicines, has called for the UK to remain in the European Union (EU), saying that EU membership enhances patients’ access to innovative clinical research.

 

“The UK already has an enviable position as one of the ‘go-to’ destinations for clinical trials, but this legacy is now under threat,” says Mike Thompson, chief executive of the ABPI, who adds that being part of the EU allows UK patients access to medical innovation to fight cancer, HIV and rare genetic diseases.

 

Research conducted by the ABPI in collaboration with Thomson Reuters, and published in November 2015, found that the UK is the top country in Europe for phase I clinical trials, second for phase II clinical trials and third for phase III clinical trials. If the UK was to leave the EU, patients would lose out, the ABPI warns.

 

In addition, the new harmonised EU Clinical Trials Regulation is set to come into force at the end of 2018, which the ABPI says will remove a lot of the red tape associated with conducting clinical trials in Europe and will enable more research. “Brexit would see patients in the UK fall out of this new system, leaving EU patients ahead in accessing the latest innovative clinical research,” it says.

 

The ABPI warns that companies would deprioritise clinical trials in the UK in favour of the collaborative and stream-lined approach offered within Europe.

 

As well as hampering patient involvement in research, the association adds that exiting the EU would also harm the economic growth of the NHS, which benefits from investment made by the life sciences industry.

HDA Media And Political Bulletin – 31 May 2016

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?